Interstitial lung disease and gefitinib

New England Journal of Medicine

Volumn 363, Issue 16, 2010, Pages 1578-1580

  Murashige, Naoko ^a   Tanimoto, Tetsuya ^b   Oshima, Yasuo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ADVERSE OUTCOME; AGED; DEATH; DRUG FATALITY; DRUG SAFETY; ELDERLY CARE; GENE MUTATION; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; LETTER; LUNG NON SMALL CELL CANCER; MEDICAL PRACTICE; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; GENETICS; JAPAN; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MUTATION;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INCIDENCE; JAPAN; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MUTATION; PRODUCT SURVEILLANCE, POSTMARKETING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77957942161     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1008506     Document Type: Letter

References (3)

1. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
2. Pharmaceuticals and Medical Devices Agency. Information on case reports with suspected adverse events. (http://www.info.pmda.go.jp/fukusayou/menu- fukusayou-attention.html.)
3. Yoshida S. The results of gefitinib prospective investigation. Med Drug J 2005;41:772-89.